Aniko R.
- Country
- Hungary
- Department
- Oncology
Research Overview
- A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS<50% Non-squamous Non-small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung07)
- A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
- A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Data & Insights
Has run more than one trial at 196 of 453 partner sites.
Specializations
Thoracic oncology
Clinical research activity is strongly centered on non-small cell lung cancer and small cell lung cancer, including advanced, metastatic, resectable, and unresectable disease settings. The portfolio also includes interest in biomarker-defined populations and treatment-resistant disease.
- Non-small cell lung cancer
- Small cell lung cancer
- Metastatic lung cancer
- Resectable lung cancer
Therapeutic focus extends to immunotherapy, targeted therapy, and combination strategies in lung malignancies.
Breast cancer and HER2-directed therapy
The investigator is involved in studies across hormone receptor-positive, HER2-negative, HER2-positive, and triple-negative breast cancer, with attention to locally advanced, metastatic, and early-stage disease.
- Hormone receptor-positive breast cancer
- HER2-positive metastatic breast cancer
- Triple-negative breast cancer
- Early-stage breast cancer
Research interests include antibody-drug conjugates, endocrine-based treatment, and HER2-targeted combinations.
Urologic and genitourinary cancers
Clinical trial involvement covers urothelial carcinoma, muscle-invasive bladder cancer, renal cell carcinoma, and prostate cancer, reflecting a broad focus on advanced genitourinary malignancies.
- Urothelial carcinoma
- Muscle-invasive bladder cancer
- Renal cell carcinoma
- Metastatic castration-resistant prostate cancer
Therapeutic domains include checkpoint inhibition, antibody-drug conjugates, and perioperative oncology care.
Gastrointestinal and head and neck oncology
The research landscape includes esophageal cancer, gastric and gastroesophageal junction cancer, colorectal cancer, and head and neck squamous cell carcinoma, with emphasis on advanced and resectable disease settings.
- Esophageal carcinoma
- Gastric and gastroesophageal junction cancer
- Colorectal cancer
- Head and neck squamous cell carcinoma
Investigational interest is centered on immuno-oncology and perioperative treatment strategies.
Cardiometabolic, respiratory, and inflammatory disease
Beyond oncology, the investigator is linked to studies in atherosclerotic cardiovascular disease, atrial fibrillation, heart failure, type 2 diabetes mellitus, obesity, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis, and psoriatic arthritis.
- Atherosclerotic cardiovascular disease
- Atrial fibrillation
- Chronic obstructive pulmonary disease
- Rheumatoid arthritis
Therapeutic interest includes cardiovascular prevention, bronchodilator therapy, and immune-mediated inflammatory disease treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.